ADVANCED MELANOMA

This study tests whether a blood test (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) to a two-drug combination (nivolumab and relatlimab) for people with advanced melanoma. About 90 adults with metastatic or advanced melanoma will participate.…

This early-phase study tests whether adding two common drugs—naltrexone and propranolol—to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma. The drugs target stress pathways that may help tumors grow. About 12 adults with stage 3 or 4 me…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 adults will receive treatment based on their tumor's unique markers. The goal is to see if this approach leads to a major or complete response in…

This early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will take …

This study tests whether the drug tebentafusp, alone or combined with pembrolizumab, helps people with advanced melanoma live longer compared to standard treatments. It includes about 540 adults with a specific genetic marker (HLA-A*02:01) whose melanoma has worsened after prior …

This study tests a treatment called TIL therapy for people with advanced melanoma that hasn't responded to standard treatments. Doctors take immune cells from a patient's tumor, grow more of them in a lab, and put them back into the patient to help fight the cancer. The goal is t…

This early-stage study tests a new drug called AB821 in about 50 adults with advanced melanoma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Participants receive AB821 every two weeks, …

This early-stage trial tests a new treatment called LauT-1 for people with advanced melanoma (a type of skin cancer) or sarcoma (a rare cancer of connective tissues). The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer …

This study is for people with advanced melanoma that has stopped responding to standard immunotherapy. Researchers are testing whether a combination of three drugs—fianlimab, cemiplimab, and ipilimumab—can shrink tumors or slow the cancer's growth. The trial will enroll 88 adults…

This phase 3 trial tests whether adding an experimental drug (IMC-F106C) to the standard immunotherapy nivolumab works better than nivolumab alone for people with advanced melanoma. About 680 adults with a specific genetic marker (HLA-A*02:01) who have not had prior treatment wil…

This Phase 3 study tests whether an experimental cancer-killing virus (vusolimogene oderparepvec) combined with the immunotherapy nivolumab works better than standard treatments for people with advanced melanoma that has worsened after prior immunotherapy. About 400 participants …

This early-phase study tests a new treatment for advanced melanoma that has stopped responding to standard immunotherapy. It combines specially trained natural killer cells (either from the patient or a donor) with two immunotherapy drugs, nivolumab and relatlimab. The goal is to…

This study tests whether adding the experimental drug EIK1001 to the standard immunotherapy pembrolizumab helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive eithe…

This study tests an experimental treatment for adults with advanced melanoma who are already on immunotherapy and planning surgery. The treatment combines focused ultrasound (using sound waves to heat and destroy tumor tissue) with an injection of a drug called polyICLC that acti…

This study tests a new drug, T3011, in 42 people with advanced melanoma that has spread. The main goals are to check safety and see if tumors shrink. Participants must have measurable tumors and be well enough for daily activities. This is an early-phase trial, so the focus is on…

This phase 2 trial tests a new treatment called LM103 TILs for people with advanced melanoma that has not responded to at least two prior therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then infused back to attack the cancer. The…

This study is testing a new drug called LBL-024, either alone or combined with other treatments (LBL-007 or toripalimab), in people with advanced melanoma that has spread. The goal is to see if these combinations can shrink tumors or slow the disease. About 200 adults will take p…

This study looks at whether high-intensity exercise and a high-fiber diet are possible and helpful for people with advanced melanoma who are receiving immunotherapy. The goal is to see if these lifestyle changes can improve gut health and immune function. The study will involve 4…

This early-phase study tests whether a new gold nanoparticle treatment (Au-TMP) is safe when injected into tumors, followed by radiation and an immunotherapy drug (Toripalimab). It involves 6 adults with advanced melanoma that cannot be surgically removed. The main goal is to che…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…